Last reviewed · How we verify
BMS-986489
BMS-986489 is an anti-inflammatory agent.
BMS-986489 is an anti-inflammatory agent. Used for Treatment of systemic lupus erythematosus.
At a glance
| Generic name | BMS-986489 |
|---|---|
| Sponsor | SCRI Development Innovations, LLC |
| Drug class | IL-1β inhibitor |
| Target | IL-1β |
| Modality | Small molecule |
| Therapeutic area | Inflammation |
| Phase | Phase 2 |
Mechanism of action
It works by inhibiting the activity of interleukin-1 beta (IL-1β), a cytokine involved in the inflammatory response. This action is expected to reduce inflammation and potentially treat various inflammatory diseases.
Approved indications
- Treatment of systemic lupus erythematosus
Common side effects
- Injection site reactions
- Headache
- Nausea
Key clinical trials
- A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). (PHASE3)
- BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS) (PHASE2)
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BMS-986489 CI brief — competitive landscape report
- BMS-986489 updates RSS · CI watch RSS
- SCRI Development Innovations, LLC portfolio CI